1,024 results match your criteria: "Heemstede; Leiden University Medical Center S.C.; Huygens & Versteegh M.V.[Affiliation]"
Sci Transl Med
July 2022
Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Inflammatory processes induced by brain injury are important for recovery; however, when uncontrolled, inflammation can be deleterious, likely explaining why most anti-inflammatory treatments have failed to improve neurological outcomes after brain injury in clinical trials. In the thalamus, chronic activation of glial cells, a proxy of inflammation, has been suggested as an indicator of increased seizure risk and cognitive deficits that develop after cortical injury. Furthermore, lesions in the thalamus, more than other brain regions, have been reported in patients with viral infections associated with neurological deficits, such as SARS-CoV-2.
View Article and Find Full Text PDFNeurooncol Pract
August 2022
Department of Medical Psychology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Background: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to corticosteroid treatment.
Methods: Using baseline data (ie, prior to randomization) of European Organization for Research and Treatment of Cancer (EORTC) trial 26101, we performed regression analysis to assess the predictive value of corticosteroid intake on performance of the EORTC brain tumor clinical trial NCF test battery.
Lancet Neurol
August 2022
Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands; UCL Queen Square Institute of Neurology, University College London, London, UK; Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands. Electronic address:
Orthostatic hypotension is an unusually large decrease in blood pressure on standing that increases the risk of adverse outcomes even when asymptomatic. Improvements in haemodynamic profiling with continuous blood pressure measurements have uncovered four major subtypes: initial orthostatic hypotension, delayed blood pressure recovery, classic orthostatic hypotension, and delayed orthostatic hypotension. Clinical presentations are varied and range from cognitive slowing with hypotensive unawareness or unexplained falls to classic presyncope and syncope.
View Article and Find Full Text PDFFront Neurosci
June 2022
Sleep-Wake Centre, Stichting Epilepsie Instellingen Netherland (SEIN), Heemstede, Netherlands.
The brain activation patterns related to sleep resistance remain to be discovered in health and disease. The maintenance of wakefulness test (MWT) is an objective neuropsychological assessment often used to assess an individual's ability to resist sleep. It is frequently used in narcolepsy type 1, a disorder characterized by impaired sleep-wake control and the inability to resist daytime sleep.
View Article and Find Full Text PDFEpilepsy Res
August 2022
Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada; Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, The Netherlands; Department of Neurosciences and School of Public Health, Université of Montréal, Canada. Electronic address:
Objective: Our study describes adults in Canada between 2009 and 2013 receiving at least one antiseizure medication (ASM) at the end of a hospitalization for newly-diagnosed epilepsy, with a focus on the type of ASM prescribed, changes in drug prescriptions after one year, and how this differs between younger and older adults.
Methods: Canada-wide data from the Discharge Abstract Database and the National Prescription Drug Utilization Information System database from 2009 to 2013 were used to identify individuals hospitalized with newly-diagnosed epilepsy and prescribed an ASM at the end of this hospitalization. We classified ASMs into enzyme inducing (EIASM) and non-enzyme inducing (non-EIASM).
Brain Sci
June 2022
Department of Physiology and Pharmacology, Istituto Pasteur-Fondazione Cenci Bolognetti, University of Rome Sapienza, 00185 Rome, Italy.
Focal cortical dysplasia (FCD) type II is an epileptogenic malformation of the neocortex, as well as a leading cause of drug-resistant focal epilepsy in children and young adults. The synaptic dysfunctions leading to intractable seizures in this disease appear to have a tight relationship with the immaturity of GABAergic neurotransmission. The likely outcome would include hyperpolarizing responses upon activation of GABARs.
View Article and Find Full Text PDFSleep Med
September 2022
Interdisciplinary Center of Sleep Medicine, Charité - Universitätsmedizin Berlin, Germany; Saratov State University, Saratov, Russia.
Objective: In 2010, a questionnaire-based study on obstructive sleep apnea (OSA) management in Europe identified differences regarding reimbursement, sleep specialist qualification, and titration procedures. Now, 10 years later, a follow-up study was conducted as part of the ESADA (European Sleep Apnea Database) network to explore the development of OSA management over time.
Methods: The 2010 questionnaire including questions on sleep diagnostic, reimbursement, treatment, and certification was updated with questions on telemedicine and distributed to European Sleep Centers to reflect European OSA management practice.
Epilepsia
August 2022
Charles Shor Epilepsy Center, Neurological Institute, Cleveland, Ohio, USA.
Ongoing challenges in diagnosing focal cortical dysplasia (FCD) mandate continuous research and consensus agreement to improve disease definition and classification. An International League Against Epilepsy (ILAE) Task Force (TF) reviewed the FCD classification of 2011 to identify existing gaps and provide a timely update. The following methodology was applied to achieve this goal: a survey of published literature indexed with ((Focal Cortical Dysplasia) AND (epilepsy)) between 01/01/2012 and 06/30/2021 (n = 1349) in PubMed identified the knowledge gained since 2012 and new developments in the field.
View Article and Find Full Text PDFNat Sci Sleep
May 2022
Center for Sleep Medicine, Sleep Research and Epileptology, Klinik Barmelweid AG, Barmelweid, Aargau, Switzerland.
Purpose: Narcolepsy type-1 (NT1) is a rare chronic neurological sleep disorder with excessive daytime sleepiness (EDS) as usual first and cataplexy as pathognomonic symptom. Shortening the NT1 diagnostic delay is the key to reduce disease burden and related low quality of life. Here we investigated the changes of diagnostic delay over the diagnostic years (1990-2018) and the factors associated with the delay in Europe.
View Article and Find Full Text PDFEpilepsia Open
September 2022
UMCU, Utrecht, The Netherlands.
Objective: To assess the performance of a multimodal seizure detection device, first tested in adults (sensitivity 86%, PPV 49%), in a pediatric cohort living at home or residential care.
Methods: In this multicenter, prospective, video-controlled cohort-study, nocturnal seizures were detected by heartrate and movement changes in children with epilepsy and intellectual disability. Participants with a history of >1 monthly major motor seizure wore Nightwatch bracelet at night for 3 months.
CNS Drugs
June 2022
Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, The Netherlands.
Drug-resistant epilepsy is associated with poor health outcomes and increased economic burden. In the last three decades, various new antiseizure medications have been developed, but the proportion of people with drug-resistant epilepsy remains relatively unchanged. Developing strategies to address drug-resistant epilepsy is essential.
View Article and Find Full Text PDFEur J Cancer
July 2022
European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
Introduction: The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) measures 15 health-related quality of life (HRQoL) scales relevant to the disease and treatment of patients with cancer. A study by Martinelli (2011) demonstrated that these scales could be grouped into three main clusters: physical, psychological and gastrointestinal. This study aims to validate Martinelli's findings in an independent dataset and evaluate whether these clusters are consistent across cancer types and patient characteristics.
View Article and Find Full Text PDFSleep
May 2022
Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Study Objectives: The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hypocretin-1 levels (111-200 pg/mL) and the diagnostic value of cataplexy characteristics in individuals with central disorders of hypersomnolence.
Methods: Retrospective cross-sectional study of 355 people with known CSF hypocretin-1 levels who visited specialized Sleep-Wake Centers in the Netherlands.
Sleep
July 2022
Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Study Objectives: The most sensitive and specific investigative method for the diagnosis of narcolepsy type 1 (NT1) is the determination of hypocretin-1 (orexin-A) deficiency (≤110 pg/mL) in cerebrospinal fluid using a radioimmunoassay (RIA). We aimed to assess the reliability of the Phoenix Pharmaceuticals hypocretin-1 RIA, by determining the lower limit of quantification (LLOQ), the variability around the cutoff of 110 pg/mL, and the inter- and intra-assay variability.
Methods: Raw data of 80 consecutive hypocretin-1 RIAs were used to estimate the intra- and inter-assay coefficient of variation (CV).
J Cancer Surviv
April 2024
Department of Medical Psychology and Brain Tumor Center Amsterdam at Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Purpose: Cancer-related neurocognitive impairment and poor sleep are prevalent in cancer survivors and have a negative impact on their quality of life. This systematic review studies the association between sleep disturbance and neurocognitive functioning, as well as the potential positive effects of sleep interventions on neurocognitive functioning in cancer survivors. In addition, we aimed at determining the potential positive effects of sleep interventions on neurocognitive functioning in this population.
View Article and Find Full Text PDFArthritis Care Res (Hoboken)
May 2023
Leiden University Medical Center, Leiden, and Haaglanden Medical Center, The Hague, The Netherlands.
Objective: To evaluate the prevalence and impact of cognitive impairment on health-related-quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE) and neuropsychiatric (NP) symptoms.
Methods: Patients with SLE and NP symptoms referred to the Leiden NPSLE clinic (2007-2019) were included. In a multidisciplinary evaluation, NP symptoms were attributed to SLE (NPSLE: inflammatory, ischemic, or both combined) or other causes.
Psychoneuroendocrinology
July 2022
Amsterdam UMC location Vrije Universiteit Amsterdam, Psychiatry,DeBoelelaan 1117, Amsterdam,The Netherlands; Amsterdam Neurosciences, Mood, Anxiety, Psychosis, Stress, and Sleep (MAPSS),Amsterdam, The Netherlands. Electronic address:
Stress initiates a cascade of (neuro)biological, physiological, and behavioral changes, allowing us to respond to a challenging environment. The human response to acute stress can be studied in detail in controlled settings, usually in a laboratory environment. To this end, many studies employ acute stress paradigms to probe stress-related outcomes in healthy and patient populations.
View Article and Find Full Text PDFNeurology
June 2022
From the Sleep Wake Center SEIN Heemstede (J.K.G., R.F., G.J.L.), Stichting Epilepsie Instellingen Nederland, Heemstede; Department of Neurology and Clinical Neurophysiology (J.K.G., R.F., G.J.L.), Leiden University Medical Center; Department of Anatomy and Neurosciences (J.K.G., S.M.), Amsterdam UMC (Location VUmc), the Netherlands; Center for Sleep Medicine, Sleep Research and Epileptology (Z.Z., R.K.), Klinik Barmelweid AG, Barmelweid, Switzerland; Leiden Observatory (M.S.S.L.O.), Leiden University, the Netherlands; Sleep-Wake Disorders Unit (Y.D., L.B.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (Y.D., L.B.); Institute for Neurosciences of Montpellier INM (Y.D., L.B.), Univ Montpellier, INSERM, France; Neurology Department (G.M.), Hephata Klinik, Schwalmstadt, Germany; Department of Biomedical, Metabolic and Neural Sciences (G.P.), University of Modena and Reggio Emilia; IRCCS Istituto delle Scienze Neurologiche di Bologna (G.P, F.P.), Bologna, Italy; Neurophysiology and Sleep Disorders Unit (R.d.R.-V.), Hospital Vithas Nuestra Señora de América, Madrid; Neurology Service (J.S.C.), Institut de Neurociències Hospital Clínic, University of Barcelona, Spain; Neurology Department and Centre of Clinical Neurosciences (K.S.), First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Helsinki Sleep Clinic (M.P.), Vitalmed Research Center, Finland; Sleep Medicine Center Kempenhaeghe (S.O.), Heeze; Eindhoven University of Technology (S.O.), the Netherlands; Sleep and Epilepsy Unit-Clinical Neurophysiology Service (R.P.-A.), University General Hospital Gregorio Marañón, Research Institute Gregorio Marañón; University Complutense of Madrid (R.P.-A.), Spain; Center for Investigation and Research in Sleep (R.H.), Lausanne University Hospital, Switzerland; Serviço de Neurofisiologia (A.M.d.S.), Hospital Santo António/Centro Hospitalar Universitário do Porto and UMIB-Instituto Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal; Neurology Department (B.H., A.H.), Sleep Disorders Clinic, Innsbruck Medical University, Austria; Department of Clinical Neurophysiology (A.W.), Institute of Psychiatry and Neurology, Warsaw, Poland; Department of Sleep Medicine and Neuromuscular Disorders (A.H.), University of Münster, Germany; Neurology Department (E.F.), Medical Faculty of P.J. Safarik University, University Hospital of L. Pasteur Kosice, Kosice, Slovak Republic; Neurology Department (M.M.), EOC, Ospedale Regionale di Lugano, Ticino, Switzerland; Department of Sleep Medicine (J.B.), National Institute of Mental Health, Klecany, Czech Republic; Fundacio d`Investigacio Sanitaria de les illes balears (F.C.), Hospital Universitari Son Espases, Palma de Mallorca, Spain; Department of Neurology (C.L.B., M.H.S., R.K.), Inselspital, Bern University Hospital, University of Bern, Switzerland; and Department of Biomedical and Neuromotor Sciences (F.P.), University of Bologna, Italy.
Background And Objectives: Recent studies fueled doubts as to whether all currently defined central disorders of hypersomnolence are stable entities, especially narcolepsy type 2 and idiopathic hypersomnia. New reliable biomarkers are needed, and the question arises of whether current diagnostic criteria of hypersomnolence disorders should be reassessed. The main aim of this data-driven observational study was to see whether data-driven algorithms would segregate narcolepsy type 1 and identify more reliable subgrouping of individuals without cataplexy with new clinical biomarkers.
View Article and Find Full Text PDFBMJ Open
April 2022
Orofacial Pain and Dysfunction, ACTA, Amsterdam, The Netherlands.
Introduction: A recent questionnaire-based study suggested that bruxism and painful temporomandibular disorders (TMD pain) may be more prevalent in patients with Parkinson's disease (PD) compared with controls. The presence of both bruxism and TMD pain may negatively influence patients' quality of life. The present study is designed to clinically and more objectively investigate the presence of bruxism and TMD pain in patients with PD.
View Article and Find Full Text PDFSleep
August 2022
Stichting Epilepsie Instellingen Nederland, Sleep-Wake Center, Heemstede, The Netherlands.
Study Objectives: To review the Maintenance of Wakefulness Test (MWT) as assessment of daytime sleepiness in the evaluation of treatment effects and driving fitness in central disorders of hypersomnolence (CDH).
Methods: We performed a scoping review of studies using the MWT in patients with CDH (i.e.
Sleep Med
April 2022
Leiden University Medical Centre, Department of Neurology, Leiden, the Netherlands; Sleep Wake Centre, Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands.
Epilepsy Res
May 2022
Department of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK; Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire SL9 0RJ, UK.
Objective: To estimate the cost and time taken to evaluate adults with drug-resistant focal epilepsy for potentially curative surgery.
Methods: We reviewed data on 100 consecutive individuals at a tertiary referral center evaluated for epilepsy surgery in 2017. The time elapsed between referral and either surgery or a definitive decision not to progress was measured.
Neurology
May 2022
From the Departments of Neurology and Epileptology (N.S., S.S., U.B.S.H., H.L., Y.W.) and Neurodegenerative Diseases (E.L.), Hertie-Institute for Clinical Brain Research, University of Tübingen; Institute of Clinical Molecular Biology (M.P., I.H.), Christian-Albrechts-University of Kiel; Departments of Neuropediatrics (M.P., A.V.R., H.M., I.H.) and Pediatrics I (A.V.R.), University Medical Center Schleswig-Holstein, Christian-Albrechts-University, Kiel; Cologne Center for Genomics (T.B., D.L.), University of Cologne, Germany; Epilepsy Center SEIN (P.B.A.), Heemstede, the Netherlands; Epilepsiezentrum Bodensee (H.B.), Weissenau, Germany; Department of Genetics and Precision Medicine (A.B.), Danish Epilepsy Centre, Dianalund, Denmark; IRCCS Istituti delle Scienze Neurologiche di Bologna (F.B., L.L., R.M., P.T.); Department of Biomedical and Neuromotor Sciences (F.B., L.L., P.T.), University of Bologna, Italy; Department of Biomedical Sciences (R.J.B.), Cooper Medical School of Rowan University, Camden, NJ; Pediatric Neurology Unit (B.Z.B., G.H.), Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Ramat Gan; Sackler School of Medicine (B.Z.B., G.H.), Tel Aviv University, Israel; FutureNeuro SFI Research Centre (M.G.D., H.K.) and Department of Neurology, Beaumont Hospital (M.G.D., H.K.), Royal College of Surgeons in Ireland; StAR MD Programme (M.G.D.), Royal College of Surgeons in Ireland in collaboration with Blackrock Clinic, Dublin, Ireland; Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, and Department of Neuroscience (R.G., A.V.), A. Meyer Children's Hospital, University of Florence; IRCCS Istituto Giannina Gaslini (M.I., P. Striano), Genova, Italy; Epilepsy Center Frankfurt Rhine-Main, Department of Neurology (K.M.K., P.S.R., F. Rosenow), University Hospital Frankfurt; LOEWE Center for Personalized Translational Epilepsy Research (CePTER) (K.M.K., P.S.R., F. Rosenow), Goethe-University Frankfurt, Germany; Departments of Clinical Neurosciences, Medical Genetics, and Community Health Sciences (K.M.K.), Hotchkiss Brain Institute & Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Canada; Department of Neurobiology and Epilepsy Center (I.K., S.S.P.), The Cyprus Institute of Neurology and Genetics, Nicosia; Institute of Experimental Epileptology and Cognition Research and Department of Epileptology (W.S.K.), University of Bonn, Germany; Division of Medical Genetics, Department of Pediatrics (M.M., S.M.), Duke University, Durham, NC; CeGaT GmbH and Praxis für Humangenetik Tübingen (L.M.), Germany; Division Biomedical Genetics (R.O.), University Medical Center Utrecht, the Netherlands; The Genomic Unit, Sheba Cancer Research Center (B.O.), Cancer Research Center, Wohl Institute for Translational Medicine (B.O.), and The Institute for Rare Diseases, The Edmond and Lily Safra Children's Hospital (A.R.), Sheba Medical Center, Tel Hashomer, Israel; Medical School (S.S.P.), University of Nicosia, Cyprus; Department of Pediatric Neuroscience (F. Ragona, T.G.), Fondazione IRCCS Istituto Neurologico Carlo Besta, Member of the ERN EpiCARE, Milan, Italy; Sheba Medical Center, Tel-Hashomer; Sackler Faculty of Medicine (A.R.), Tel Aviv University, Israel; Departments of Neurosciences, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (P. Scudieri, P. Striano, F. Zara), University of Genova, Italy; Clinical Genetics and Genomics Department (G.A.T.), The Cyprus Institute of Neurology and Genetics, Nicosia; Department of Neurology (F. Zahnert), Epilepsy Center Hessen, Philipps-University Marburg, Germany; Division of Neurology (E.M.G., I.H.), The Epilepsy NeuroGenetics Initiative (ENGIN) (E.M.G., I.H.), and Department of Biomedical and Health Informatics (DBHi) (I.H.), Children's Hospital of Philadelphia, PA; Epilepsy Center, Neurological Institute (D.L.), and Genomic Medicine Institute, Lerner Research Institute (D.L.), Cleveland Clinic, OH; Stanley Center for Psychiatric Research (D.L.), The Broad Institute of Harvard and MIT, Cambridge, MA; Analytic and Translational Genetics Unit (D.L.), Massachusetts General Hospital, Boston; Luxembourg Centre for Systems Biomedicine (P.M.), University Luxembourg; Department of Neurology (I.H.), Perelman School of Medicine, University of Pennsylvania, PA; and Department of Epileptology and Neurology (Y.W.), University of Aachen, Germany.